Century Therapeutics CEO Pfeiffenberger buys 52,000 shares at $0.58 amid 30-day 31.3% rally from near 52-week lows
Pfeiffenberger purchased 52,000 shares at $0.58 on 2025-12-12, increasing his holdings to 3.32M shares. The purchase occurred during a period of significant positive price momentum: the stock has risen 31.3% over 30 days and 26.0% over 90 days, though it remains -54.1% from its 52-week high of $1.35 and trades at a $0.62 current price. The company is unprofitable with net income of $-34.4M against quarterly revenue of $109.2M, but has demonstrated strong topline growth of 194.8% year-over-year. The insider's own track record is minimal—one prior buy across all tickers with outcome not yet measurable—providing limited context for interpreting conviction. This buy represents a 1.6% increase to holdings and follows another Century Therapeutics purchase on 2025-11-19, suggesting sustained accumulation during a recovery phase off depressed valuations.
CEO Pfeiffenberger buys 35,000 IPSC shares at $0.50; stock down 71.5% from 52-week high despite 194.8% revenue growth
Brent Pfeiffenberger, President and CEO of Century Therapeutics, purchased 35,000 shares at $0.50 on 2025-11-19, expanding his holdings to 3,271,453 shares. The transaction occurs in a challenging backdrop: the stock trades at $0.49 (current price), off 71.5% from the 52-week high of $1.72 and down 13.3% over the prior 30 days. Despite material top-line expansion (annual revenue growth of 194.8%), the company remains unprofitable with a $-34.4M net loss in the most recent period, and the market cap of $42.8M now represents a significant discount to the company's quarterly revenue of $109.2M. A CEO equity purchase at a depressed valuation amid revenue acceleration may warrant attention to whether management sees near-term catalysts or turnaround mechanics, but the absence of a broader insider transaction pattern limits what can be concluded from this single trade.
